Under the terms of the agreement, Maxygen will transfer to Sanofi Pasteur a portfolio of preclinical dengue antigens for development and worldwide commercialization of a second generation vaccine. In addition to royalties, total event payments to Maxygen, including an upfront fee, could total $24.5 million.
Russell Howard, CEO of Maxygen, said: “This agreement will allow Maxygen’s dengue antigen technology to be advanced using Sanofi Pasteur’s vaccine research and development expertise and worldwide commercial infrastructure. This allows us to create value from our vaccine discovery assets while maintaining our internal focus on protein therapeutics.”